Literature DB >> 6103860

Effects of [Asu1,7]-eel calcitonin on gastric somatostatin and gastrin release.

T Chiba, T Taminato, S Kadowaki, Y Goto, K Mori, Y Seino, H Abe, K Chihara, S Matsukura, T Fujita, T Kondo.   

Abstract

Effects of [Asu1,7]-eel calcitonin on gastric somatostatin and gastrin secretion were studied by using the isolated perfused rat stomach. [Asu1,7]-eel calcitonin (10(-9)--10(-7)M) caused a simultaneous dose-dependent increase of gastric somatostatin release and decrease of gastrin secretion, with a significant correlation between these two. The demonstration of calcitonin stimulation of gastric somatostatin release raises the possibility of somatostatin-mediated suppression of gastrin secretion by calcitonin.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6103860      PMCID： PMC1419353          DOI： 10.1136/gut.21.2.94

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  25 in total

1.  Calcitonin and exocrine pancreatic secretion in man: inhibition of enzymes stimulated by CCK-pancreozymin, caerulein, or calcium--no response to vagal stimulation.

Authors:  J Hotz; H Goebell; R Ziegler
Journal:  Gut       Date:  1977-08       Impact factor: 23.059

2.  Somatostatin release from isolated perfused rat stomach.

Authors:  T Chiba; Y Seino; Y Goto; S Kadowaki; T Taminato; H Abe; Y Kato; S Matsukura; M Nozawa; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1978-05-30       Impact factor: 3.575

3.  Single cellular origin of somatostatin and calcitonin in the rat thyroid gland.

Authors:  S Van Noorden; J M Polak; A G Pearse
Journal:  Histochemistry       Date:  1977-08-22

4.  Effect of calcium and calcitonin on gastrin and gastric secretion in cats.

Authors:  H D Becker; S J Konturek; D D Reeder; J C Thompson
Journal:  Am J Physiol       Date:  1973-08

5.  [Inhibition of gallbladder contractions using calcitonin].

Authors:  K Winckler; R D Hesch; H Schmidt
Journal:  Dtsch Med Wochenschr       Date:  1973-05-04       Impact factor: 0.628

6.  Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells.

Authors:  J M Polak; A G Pearse; L Grimelius; S R Bloom
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

7.  Stability of [Asu1,7]-eel calcitonin and eel calcitonin in vitro and in vivo.

Authors:  H Yamauchi; M Shiraki; M Otani; M Matsuo; H Orimo
Journal:  Endocrinol Jpn       Date:  1977-06

8.  Inhibition by somatostatin (growth-hormone release-inhibiting hormone, GH-RIH) of gastric acid and pepsin and G-cell release of gastrin.

Authors:  A A Barros D'sa; S R Bloom; J H Baron
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

9.  Hypergastrinemia in hyperthyroidism.

Authors:  Y Seino; S Matsukura; Y Miyamoto; Y Goto; T Taminato; H Imura
Journal:  J Clin Endocrinol Metab       Date:  1976-10       Impact factor: 5.958

10.  [Influence of somatostatine on plasma level of calcitonin in the calf and the swine].

Authors:  J P Barlet; J M Garel
Journal:  C R Seances Soc Biol Fil       Date:  1975
View more
  5 in total

1.  Effect of calcitonin on gastric emptying in patients with an active duodenal ulcer.

Authors:  K Jonderko
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

2.  Inhibition of gastric secretion and stress-induced ulcers by intravenous Asu(1,7)eel-calcitonin independent of vasopressin.

Authors:  G Clementi; A Prato; G Conforto; E Rapisarda; A Caruso; O Mangano; U Scapagnini
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

3.  Release of somatostatin-like immunoreactivity from the perfused canine thyroid. Selective stimulatory effect of calcium ions.

Authors:  P Laurberg; H Orskov
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

4.  Inhibition of restraint stress by systemic (Asu1,7) eel-calcitonin.

Authors:  G Clementi; A Prato; E Rapisarda; G Conforto; O Mangano; A Caruso; U Scapagnini
Journal:  J Endocrinol Invest       Date:  1985-12       Impact factor: 4.256

5.  The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).

Authors:  Peter R van Dijk; Gijs W D Landman; Larissa van Essen; Joachim Struck; Klaas H Groenier; Henk J G Bilo; Stephan J L Bakker; Nanne Kleefstra
Journal:  BMC Endocr Disord       Date:  2015-04-14       Impact factor: 2.763
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.